Genentech Announces New STEM Education Initiative to Support South San Francisco Schools
The Changing Face of Skin Cancer
Take a deep dive under the skin and read how we've started to make progress in treating the most common type of cancer.
Today's STEM professionals can help inspire the leaders of tomorrow.
Renewing Our Commitment to Sustainability
We reached our 2014 sustainability goals, but we're not stopping there. Learn more about what we're working on for 2020!
From Our Labs: Cell Culture Shock
There’s a deeply unsettling problem in the world of cell cultures used for scientific research. We’re tackling it head-on with an ambitious new solution.
On February 6, 2015, the FDA approved a Genentech Medicine for the treatment of diabetic retinopathy in people with diabetic macular edema (DME).
From Our Labs
Genentech scientists have found that a protein called DLK may play a role in many types of neurodegeneration, with implications for diseases like Alzheimer’s and ALS.
Shutting Down Pain
Many pain medicines were discovered either by accident or by exploring traditional remedies; we're trying to understand the biology of pain using target-based drug discovery.
On November 14, 2014, a Genentech medicine received FDA approval for use in a specific type of platinum-resistant ovarian cancer.
2014 ACR Annual Meeting
Presentations, Posters, and Papers galore. Check out our ACR 2014 newsroom to learn more about our commitment to rheumatology.
2014 AAO Annual Meeting
Genentech will present important new ophthalmic data at the 118th Annual Meeting of the American Academy of Ophthalmology (AAO) from October 18-21 in Chicago.
On October 15, 2014, the FDA approved a medicine for the treatment of idiopathic pulmonary fibrosis (IPF).
Genentech Agrees to Acquire Seragon to Strengthen Breast Cancer Pipeline
Read about Genentech’s planned acquisition of Seragon.
New Insights on Breast Cancer Research
With the recent acquisition of Seragon, Genentech is excited to add a new class of investigational medicines known as SERDs to our pipeline.
Sunshine Act: Increasing Transparency
Genentech fully supports efforts to increase transparency around the partnership between the industry and healthcare professionals.